Disease control in patients with non ‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy

ConclusionsOur findings indicated that maintaining the dose of PEM after the second treatment cycle in patients with NSCLC, along with concurrent use of Bev and the presence of TTF-1 positivity, could enhance disease control rates and extend survival.

Source: Thoracic Cancer - March 15, 2024 Category: Cancer & Oncology Authors: Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa Tags: ORIGINAL ARTICLE Source Type: research